✨ Free AI Report
Neumora Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Neumora Therapeutics, Inc.
Company Research

Neumora Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Neumora Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Multiple 2026 data readouts offer near-term validation opportunities for Neumora's precision neuroscience approach, with potential value inflection if trials succeed. Clinical-stage biotech with differentiated pipeline and promising early data (NMRA-511 showed clinically meaningful effect in Alzheimer's agitation; NMRA-215 showed class-leading weight loss). Near-term catalysts are strong but execution risk.

What is Neumora Therapeutics, Inc.'s industry? Neumora Therapeutics, Inc. (neumoratx.com) operates in Biopharmaceutical - Clinical Stage CNS/Neuroscience. AskCyborg classifies Neumora Therapeutics, Inc. under Biopharmaceutical - Clinical Stage CNS/Neuroscience in its company registry.

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company employs a precisio...

6/ 10Solid

Cyborg Score thesis

Multiple 2026 data readouts offer near-term validation opportunities for Neumora's precision neuroscience approach, with...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Clinical Stage CNS/Neuroscience
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Neumora Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Neumora Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Neumora Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Neumora Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Neumora Therapeutics, Inc. Overview

Pro stress-test →

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company employs a precision medicine approach leveraging translational, clinical, and computational tools to target unmet medical needs in CNS diseases with best-in-class pharmacology.

Strategic Profile

Pro stress-test →

Neumora's competitive advantage lies in its multi-program pipeline targeting innovative mechanisms of action including kappa opioid receptor antagonism, vasopressin 1a receptor antagonism, and M4 positive allosteric modulation. Multiple clinical data readouts expected in 2026, including KOASTAL-2 and KOASTAL-3 trials, present significant value creation opportunities if successful.

Competitive Landscape

Pro stress-test →

Neumora competes within the CNS drug development space against larger biotech and pharma companies targeting neuropsychiatric and neurodegenerative diseases. Key competitive advantages include novel mechanism targets (KOR, V1aR, M4 PAM) and precision medicine platform. Major competitors include established players like Eli Lilly, Biogen, and emerging biotech focused on Alzheimer's and psychiatric indications.

Industry Context

Neumora Therapeutics, Inc. operates in Biopharmaceutical - Clinical Stage CNS/Neuroscience.

Key facts

Founded: 2019 · Headquarters: Watertown, Massachusetts · Revenue: $0 · Market cap: $109.9M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Neumora Therapeutics, Inc..

  • NMRA-511 demonstrated clinically meaningful 15.7-point reduction in Alzheimer's disease agitation (CMAI total score), outperforming pre-specified comparators
  • NMRA-215 obesity program shows class-leading results: 19% weight loss monotherapy, up to 26% in combination with semaglutide
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Portfolio updates including positive preclinical NLRP3 inhibitor data for NMRA-215 obesity program
  • October 2025Announced class-leading obesity results and plans to initiate Phase 1 study with NMRA-215
  • +1 moreTrack every material event for Neumora Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Neumora Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DonanemabAnti-amyloid antibody for Alzheimer's disease→LecanemabAnti-amyloid monoclonal antibody for early Alzheimer's→GLP-1 agonistsObesity and weight loss treatments→

Compare Neumora Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Neumora Therapeutics, Inc. operates in Biopharmaceutical - Clinical Stage CNS/Neuroscience. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Clinical Stage CNS/Neuroscience research →
NEW · MCP server

Ask your AI assistant about Neumora Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Neumora Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Neumora Therapeutics, Inc. do this quarter?”
“Is Neumora Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Neumora Therapeutics, Inc. do?+
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company employs a precisio...
What is Neumora Therapeutics, Inc.'s Cyborg Score?+
Neumora Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Neumora Therapeutics, Inc.'s main competitors?+
Named competitors include Donanemab, Lecanemab, GLP-1 agonists. The full competitive landscape is in the AskCyborg report.
How can I get the full Neumora Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Neumora Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Neumora Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Clinical Stage CNS research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Anavex Life Sciences Corp.